Sincalide (Cholecystokinin octapeptide, CCK‐8) 是一种速效胆囊收缩素 (CCK) 的 氨基酸多肽激素类似物，在胆囊造影术中静脉使用。CCK‐8 是 CCK 的一个主要生物活性片段，它保留了 CCK 的大部分生物活性。可通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病。其增加胆汁的分泌，使胆囊收缩并使 Oddi 的括约肌松弛，从而使胆汁排入十二指肠。

Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK.

Solid

Sincalide (Cholecystokinin octapeptide, CCK‐8), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. CCK‐8 also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway. has not independently confirmed the accuracy of these methods. They are for reference only.

Sincalide (Cholecystokinin octapeptide, CCK‐8) (i.p.; 50 μg/kg/d; for 4 weeks) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Mo

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture and light, under nitrogenPowder -80°C 2 years；-20°C 1 ye

D-{SO3H-Tyr}-MGWMDF-NH2

[1]. Maher KA et al. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991 Oct;14(2):98-100.
[2]. Ziessman HA. Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues. J Nucl Med Technol. 2019 Sep;47(3):210-212.
[3]. Can Wang, et al. Protective

In Vitro: H₂O : 50 mg/mL (43.73 mM; ultrasonic and adjust pH to 11 with NH3·H2O)DMF : 50 mg/mL (43.73 mM; Need ultrasonic)配制储备液